BioProcess Solutions - Company finances
|
EUR
|
2018
From: 2018-04-23
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 316,500 | 22,190 | - | - | 3,804 | 56,049 | 202,788 | 387,873 |
| Profit before tax | - | - | - | - | - | - | 21,135 | 4,773 |
| Net profit | -391,675 | -1,570 | -385,952 | -4,518 | -4,835 | 850 | 18,156 | 3,880 |
| Equity | 8,325 | 6,755 | 14,048 | 11,085 | 8,195 | 9,045 | 27,201 | 31,081 |
| Liabilities | 31,796 | 18 | 0 | 22 | 52 | 9,457 | 3,332 | 125,282 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 40,085 | 6,763 | 14,028 | 11,091 | 8,198 | 18,405 | 30,419 | 172,649 |
| Total assets | 40,085 | 6,763 | 14,028 | 11,091 | 8,198 | 18,405 | 30,419 | 172,649 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,290 | 2,932 | 496 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | -93.0% | - | - | - | +1373.4% | +261.8% | +91.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -977.1% | -23.2% | -2751.3% | -40.7% | -59.0% | 4.6% | 59.7% | 2.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -4704.8% | -23.2% | -2747.4% | -40.8% | -59.0% | 9.4% | 66.7% | 12.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -123.8% | -7.1% | - | - | -127.1% | 1.5% | 9.0% | 1.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 10.4% | 1.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.8 | 0.0 | - | 0.0 | 0.0 | 1.0 | 0.1 | 4.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 113,939 | 7,397 | - | - | 3,804 | 56,049 | 202,788 | 387,873 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BioProcess Solutions - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-11-16 | 2021-11-29 | 0.01 |
| 2021-10-18 | 2021-11-02 | 0.01 |
BioProcess Solutions - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BioProcess Solutions, UAB (code 304830911) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In 2025, the company continued to expand strongly: revenue reached €387.9K, up from €202.8K in 2024 and €56.0K in 2023, equal to 91.3% year-on-year growth and 592.0% growth over two years. Net profit fell to €3.9K in 2025 from €18.2K in 2024, but remained above the €850 reported in 2023. As a result, the net profit margin narrowed to 1.0% in 2025 from 9.0% in 2024 and 1.5% in 2023. The balance sheet also expanded significantly, with total assets rising to €172.6K in 2025 from €30.4K a year earlier. Equity increased to €31.1K, while liabilities grew to €125.3K, lifting the debt-to-equity ratio to 4.03 and leaving the equity ratio at 18.0%. For 2025, ROE was 12.5%, ROA 2.2%, and asset turnover 2.25x. Revenue per employee was €387.9K, with profit per employee of €3.9K.